Glycated Hemoglobin Testing Market Size, Share, Competitive Landscape and Trend Analysis Report, by Product Type, by Technology and, by End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

Glycated hemoglobin is used to measure three-month average plasma glucose concentration. It is a standardized test that indicates the amount of HbA1c, a special form of glycated hemoglobin, in a persons blood during the past two to four months. A glycated hemoglobin test is used to diagnose type 2 diabetes by monitoring the amount of hemoglobin bound to the glucose.

The major factors that contribute to the growth of the glycated hemoglobin testing market include increasing diabetic patients, growing geriatric population, technological advancements in diagnosing diabetes, growth in the home healthcare market, and increased R&D activities in early diagnosis and efficient disease management. However, the availability of substitutes and high costs associated with glycated hemoglobin testing hinder the market growth. Increase in diabetic population and growing awareness about POC HbA1c testing in developing countries are expected to boost the market growth in the near future.

The glycated hemoglobin testing market is segmented on the basis of product, technology, end user, and region. On the basis of product type, the market is segmented into Laboratory HbA1c testing products and point of care (POC) HbA1c testing products. Based on technology, the market is segmented into chromatography, immunoassay, and others. On the basis of end user, the market is classified into hospitals, physical examination institution, research institutions, and others. By geography, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players that operate in this market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Alere Inc., Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Bayer AG, Randox Laboratories Ltd., Tosoh Corporation, ARKRAY, Inc., and A.Menarini Diagnostics Ltd.

Key Benefits

• The study provides an in-depth analysis of the market with current trends and future estimations to elucidate imminent investment pockets.
• The report provides information about the current and upcoming trends in the market, which helps determine prevailing opportunities.
• Comprehensive analysis of factors that drive and restrict the growth of the market has been provided.
• Identification of factors that are instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale have been provided.
• Key market players within the market have been profiled in this report and their strategies are analyzed thoroughly, which help understand the competitive outlook of the global market.

  Glycated Hemoglobin Testing Market Report Highlights

Aspects	Details
By Product Type	Laboratory HbA1c Testing Products Point of Care (POC) HbA1c Testing Products
By Technology	Chromatography Immunoassay Others
By End User	Hospitals Physical Examination Institution Research Institutions Others
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players	Bayer AG, Randox Laboratories Ltd., ARKRAY, Inc., Beckman Coulter, Inc., Abbott Laboratories, A.Menarini Diagnostics Ltd., Tosoh Corporation, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Alere Inc.